Omeprazole Medication ATI Active Learning Template PDF

Preview

Summary

Omeprazole Medication ATI Active Learning Template...

Description

ACTIVE LEARNING TEMPLATE:

Medication

STUDENT NAME _____________________________________ MEDICATION Omeprazole __________________________________________________________________________

REVIEW MODULE CHAPTER ___________

pump inhibitor, antiulcer agent CATEGORY CLASS proton ______________________________________________________________________ PURPOSE OF MEDICATION

Expected Pharmacological Action Binds to an enzyme on gastric parietal cells in the presence of acidic gastric pH, preventing the final transport of hydrogen ions into the gastric lumen

Therapeutic Use Reduction of accumulation of acid in the gastric lumen with lessened gastroesophageal reflux.Healing of duodenal ulcers

Complications dizziness, drowsiness, fatigue, headache, weakness, chest pain, cutaneous lupus erythematosus, itching, rash, hypomagnesemia, C-diff associated diarrhea, abdominal pain, acid regurgitation, constipation, diarrhea, flatulence, fundic gland polyps, nausea, vomiting, acute interstitial nephritis, vitamin B12 deficiency, bone fracture, systemic lupus erythematosus

Medication Administration Administer doses before meals, preferably in the early am. Capsules and tablets should be swallowed whole. Capsules may be opened and sprinkled on cool applesauce, entire mixture should be ingested immediately and followed by a drink of water. Do Not Crush

Contraindications/Precautions hypersensitivity to omeprazole or other -zoles, concurrent use of rilpivirine. Use caution with hepatic impairment and lactation

Interactions increases levels/risk of toxicity of antifungals, cilostazol, citalopram, diazepam, flurazepam, triazolam, cyclosporine, phenytoin, saquinavir, tacrolimus, and warfarin.decreases absorption of drugs requiring acid pH, including ketoconazole, itraconazole, iron salts, dasatinib, erlotinib, nilotinib, atazanavir, nelfinavir, rilpivirine, & mycophenolate mofetil. May increase levels of digoxin and methotrexate, Voriconazole may increase levels, May decrease the antiplatelet effects of clopidogrel, Rifampin may decrease levels/responseHypomagnesemia risk of digoxin toxicity, St. John's wort

Evaluation of Medication Effectiveness Decrease in abdominal pain and/or prevention of gastric irritation and/or bleeding. Healing of duodenal ulcers can be seen on x-ray examination or endoscopy. Decrease in symptoms of GERD and erosive esophagitis. Therapy is continued for 4-8 weeks after initial episode

ACTIVE LEARNING TEMPLATES

Nursing Interventions Assess patient for epigastric or abdominal pain and occult blood in the stool, emesis, or gastric aspirate. Monitor bowel function. Diarrhea, cramping, fever, and bloody stools should be reported to HCP promptly as a sign of C-diff. associated diarrhea. May begin up to several weeks after cessation of therapy

Client Education avoid driving or other potentially dangerous activities until medication reaction is known. avoid ETOH andproducts containing aspirin or NSAIDs. Foods that may cause an increase in GI irritation should be avoided. Report onset of black, tarry stools; diarrhea; abdominal pain; or persistent headache to providor immediatly.

THERAPEUTIC PROCEDURE

A7...